In pleading guilty to off-label marketing of its AIDS-wasting drug Megace (megestrol acetate), Par Pharmaceutical entered a corporate integrity agreement that requires executives to forfeit annual performance pay for up to three years if they are discovered to be involved “in any significant misconduct.”
The corporate integrity agreement (CIA) also prohibits the company from providing incentive compensation to sales representatives based on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?